Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1701963 dose-escalation trial alone and with BI 3011441 in KRAS-mutant advanced solid tumors
jRCT2031200385Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BI 1701963 and BI 3011441 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities during MTD evaluation period and Objective response. Started Apr 2021; status: completed.
02
Drugs
BI 1701963BI 3011441
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031200385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200385.